Structure-activity Relationships of 8-styrylxanthines As A2-selective Adenosine Antagonists

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 1993 May 14

PMID 8496902

Citations 35

Authors

K A Jacobson

N Melman

B Fischer

M Maillard

A van Bergen

P J van Galen

Y Karton

Affiliations

Soon will be listed here.

Abstract

A series of substituted 8-styryl derivatives of 1,3,7-alkylxanthines was synthesized as potential A2-selective adenosine receptor antagonists, and the potency at rat brain A1- and A2-receptors was studied in radioligand binding experiments. At the xanthine 7-position, only small hydrophobic substituents were tolerated in receptor binding. 7-Methyl analogues were roughly 1 order of magnitude more selective for A2 versus A1 receptors than the corresponding 7-H analogues. 1,3-Dimethylxanthine derivatives tended to be more selective for A2-receptors than the corresponding 1,3-diallyl, diethyl, or dipropyl derivatives. Substitutions of the phenyl ring at the 3-(monosubstituted) and 3,5-(disubstituted) positions were favored. 1,3, 7-Trimethyl-8-(3-chlorostyryl)xanthine was a moderately potent (Ki vs [3H]CGS 21680 was 54 nM) and highly A2-selective (520-fold) adenosine antagonist. 1,3,7-Trimethyl-8-[(3-carboxy-1-oxopropyl)amino] styryl]xanthine was highly A2-selective (250-fold) and of enhanced water solubility (max 19 mM). 1,3-Dipropyl-7-methyl-8-(3,5-dimethoxystyryl) xanthine was a potent (Ki = 24 nM) and very A2-selective (110-fold) adenosine antagonist.

Citing Articles

1,3-Dialkylxanthine Derivatives Having High Potency as Antagonists at Human A Adenosine Receptors.

Jacobson K, Ijzerman A, Linden J Drug Dev Res. 2024; 47(1):45-53.

PMID: 38239816 PMC: 10795772. DOI: 10.1002/(sici)1098-2299(199905)47:1<45::aid-ddr6>3.0.co;2-u.

Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors.

Jacobson K, Suzuki F Drug Dev Res. 2024; 39(3-4):289-300.

PMID: 38239267 PMC: 10794911. DOI: 10.1002/(sici)1098-2299(199611/12)39:3/4<289::aid-ddr8>3.0.co;2-n.

A adenosine receptor agonists, antagonists, inverse agonists and partial agonists.

Jacobson K, Suresh R, Oliva P Int Rev Neurobiol. 2023; 170:1-27.

PMID: 37741687 PMC: 10775762. DOI: 10.1016/bs.irn.2023.08.001.

In Silico Identification of Multi-Target Ligands as Promising Hit Compounds for Neurodegenerative Diseases Drug Development.

Alov P, Stoimenov H, Lessigiarska I, Pencheva T, Tzvetkov N, Pajeva I Int J Mol Sci. 2022; 23(21).

PMID: 36362434 PMC: 9655539. DOI: 10.3390/ijms232113650.

In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Lemos A, Melo R, Preto A, Almeida J, Moreira I, Cordeiro M Curr Neuropharmacol. 2018; 16(6):786-848.

PMID: 29521236 PMC: 6080095. DOI: 10.2174/1570159X16666180308161642.

References

Shamim M, Ukena D, Padgett W, Daly J . Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. J Med Chem. 1989; 32(6):1231-7. DOI: 10.1021/jm00126a014. View

Jacobson K, Barone S, Kammula U, Stiles G . Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. J Med Chem. 1989; 32(5):1043-51. PMC: 3442263. DOI: 10.1021/jm00125a019. View

Jacobson K, van Galen P, Williams M . Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J Med Chem. 1992; 35(3):407-22. PMC: 3476067. DOI: 10.1021/jm00081a001. View

Erickson R, Hiner R, Feeney S, Blake P, Rzeszotarski W, Hicks R . 1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity. J Med Chem. 1991; 34(4):1431-5. DOI: 10.1021/jm00108a029. View

Francis J, CASH W, PSYCHOYOS S, Ghai G, Wenk P, FRIEDMANN R . Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J Med Chem. 1988; 31(5):1014-20. DOI: 10.1021/jm00400a022. View

Abiru T, Miyashita T, Watanabe Y, Yamaguchi T, Machida H, Matsuda A . Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects. J Med Chem. 1992; 35(12):2253-60. DOI: 10.1021/jm00090a017. View

Ukena D, Jacobson K, Padgett W, Ayala C, Shamim M, Kirk K . Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett. 1986; 209(1):122-8. PMC: 3469266. DOI: 10.1016/0014-5793(86)81096-1. View

Schwabe U, Trost T . Characterization of adenosine receptors in rat brain by (-)[3H]N6-phenylisopropyladenosine. Naunyn Schmiedebergs Arch Pharmacol. 1980; 313(3):179-87. DOI: 10.1007/BF00505731. View

Lohse M, Elger B, Klotz K, Schwabe U . Separation of solubilized A2 adenosine receptors of human platelets from non-receptor [3H]NECA binding sites by gel filtration. Naunyn Schmiedebergs Arch Pharmacol. 1988; 337(1):64-8. DOI: 10.1007/BF00169478. View

10.

van Galen P, Stiles G, Michaels G, Jacobson K . Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev. 1992; 12(5):423-71. PMC: 3448285. DOI: 10.1002/med.2610120502. View

11.

Shimada J, Suzuki F, Nonaka H, Ishii A, Ichikawa S . (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem. 1992; 35(12):2342-5. DOI: 10.1021/jm00090a027. View

12.

Cheng Y, Prusoff W . Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22(23):3099-108. DOI: 10.1016/0006-2952(73)90196-2. View

13.

Nikodijevic O, SARGES R, Daly J, Jacobson K . Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J Pharmacol Exp Ther. 1991; 259(1):286-94. PMC: 3425643. View

14.

Ueno M, Brookins J, Beckman B, Fisher J . A1 and A2 adenosine receptor regulation of erythropoietin production. Life Sci. 1988; 43(3):229-37. DOI: 10.1016/0024-3205(88)90312-8. View

15.

SARGES R, Howard H, Browne R, Lebel L, Seymour P, KOE B . 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J Med Chem. 1990; 33(8):2240-54. DOI: 10.1021/jm00170a031. View

16.

Choi O, Shamim M, Padgett W, Daly J . Caffeine and theophylline analogues: correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. Life Sci. 1988; 43(5):387-98. DOI: 10.1016/0024-3205(88)90517-6. View

17.

Ueeda M, Thompson R, Arroyo L, Olsson R . 2-aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor. J Med Chem. 1991; 34(4):1340-4. DOI: 10.1021/jm00108a015. View

18.

Seale T, Abla K, Shamim M, Carney J, Daly J . 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs. Life Sci. 1988; 43(21):1671-84. DOI: 10.1016/0024-3205(88)90478-x. View

19.

Barrington W, Jacobson K, Hutchison A, Williams M, Stiles G . Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A. 1989; 86(17):6572-6. PMC: 297886. DOI: 10.1073/pnas.86.17.6572. View

20.

Ji X, Stiles G, van Galen P, Jacobson K . Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling. J Recept Res. 1992; 12(2):149-69. PMC: 3429337. DOI: 10.3109/10799899209074789. View